We used a novel penile simian HIV (SHIV) transmission model to investigate if cabotegravir long-acting (CAB LA) prevents penile SHIV acquisition in macaques. Twenty-two macaques were exposed to SHIV via the foreskin and urethra once-weekly for 12 weeks. Of these, six received human-equivalent doses of CAB LA, six received oral FTC/TDF, and 10 were untreated. The efficacy of CAB LA was high (94.4% [95%CI=58.2%-99.3%]) and similar to that seen with oral FTC/TDF (94.0% [95%CI=55.1%-99.2%]). The high efficacy of CAB LA in the penile transmission model supports extending the clinical advancement of CAB LA PrEP to heterosexual men.

中文翻译：

---

长效Cabotegravir保护猕猴免于反复遭受阴茎猿猴-人类免疫缺陷病毒的感染。

我们使用了一种新颖的阴茎猿猴HIV（SHIV）传播模型来研究cabotegravir长效药物（CAB LA）是否能防止猕猴中阴茎SHIV的获得。每周一次通过包皮和尿道将22只猕猴暴露于SHIV，持续12周。其中，六剂接受人当量剂量的CAB LA，六剂接受口服FTC / TDF，而十剂未经治疗。CAB LA的疗效很高（94.4％[95％CI = 58.2％-99.3％]），与口服FTC / TDF的疗效相似（94.0％[95％CI = 55.1％-99.2％]）。CAB LA在阴茎传播模型中的高功效支持将CAB LA PrEP的临床进展扩展到异性恋男人。